|

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

RECRUITINGPhase 1Sponsored by Chugai Pharmaceutical
Actively Recruiting
PhasePhase 1
SponsorChugai Pharmaceutical
Started2026-07-24
Est. completion2030-08-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site

Summary

This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of AQUA07 when administered as single agent and in combination with lorlatinib in patients with ALK positive non-small cell lung cancer.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥ 18 years (or ≥ 20 years if required by local regulation) at time of signing Informed Consent Form
* Previously treated with at least one ALK-TKI regardless of prior chemotherapy treatment (Patients who have received only crizotinib as prior ALK-TKI treatment will not be allowed.)
* Histologically or cytologically (excluding sputum cytology) proven diagnosis of locally advanced unresectable or metastatic ALK-positive NSCLC, who have experienced disease progression during or following their most recent systemic therapy or have discontinued the therapy due to unacceptable toxicity
* Measurable disease per RECIST v1.1
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Ability and willingness to take oral medication(s)
* Adequate organ function and bone marrow reserve

Exclusion Criteria:

* Prior toxicities from anti-cancer therapy which have not resolved to Grade ≤ 1 per NCI CTCAE v5.0 excluding alopecia, vitiligo, or endocrinopathies manageable with replacement therapy
* Symptomatic, active CNS metastases or untreated CNS metastases requiring any definitive therapy.
* Severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or renal disease, or active infection), or with a history or complication of interstitial lung disease
* Significant cardiovascular disease
* Inadequately controlled hypertension
* (Part B only) Patients with prior lorlatinib treatment who experienced serious lorlatinib-related toxicities, or who experienced toxicities considered inappropriate for study participation at the discretion of the Investigator

Conditions3

ALK Positive Non-small Cell Lung CancerCancerLung Cancer

Interventions2

Locations1 site

The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030

Find trials near these locations

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.